Trial Profile
A phase 2, multi-center, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and efficacy of LymphoStat-B antibody (monoclonal anti-BLyS antibody) in subjects with systemic lupus erythematosus (SLE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Biomarker; Therapeutic Use
- Sponsors Human Genome Sciences
- 14 Nov 2022 Results of a meta-analysis by pooling individual patient MBC flow cytometry data from 1245 patients with SLE from from four randomised clinical trials (NCT00071487, NCT00410384, NCT01632241 and NCT01649765) and extensive B-cell subset phenotyping was performed prospectively by employing high-sensitivity flow cytometry (NCT03312907 and NCT03747159) presented at the ACR Convergence 2022.
- 01 Nov 2022 Results of pooled post hoc analysis (n=4170) assessing the safety (52-week) profile of belimumab versus placebo in adults with systemic lupus erythematosus from NCT00071487, NCT00424476, NCT00410384, NCT01345253, NCT01632241, NCT01484496 studies, published in the Lupus.
- 04 Jun 2022 Results of a meta-analysis by pooling individual patient MBC flow cytometry data from 1245 patients with SLE from from four randomised clinical trials (NCT00071487, NCT00410384, NCT01632241 and NCT01649765) and extensive B-cell subset phenotyping was performed prospectively by employing high-sensitivity flow cytometry (NCT03312907 and NCT03747159) presented at the 23rd Annual Congress of the European League Against Rheumatism